Interdisciplinary Management of Patients With Severe Asthma

Optimizing Management Strategies in Moderate-to-Severe Atopic Dermatitis

Physicians need further education to fully understand and implement current advanced therapies and distinguish the pathways of disease and targets addressed by newer therapies. This educational activity will provide key clinical data on new and emerging treatments, focusing on the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway in the context of evolving understanding of disease immunopathogenesis.

Mechanistic Insights and Evolving Treatment Options

This educational activity will address the pharmacist’s critical role in HCV elimination, guideline-based HCV testing and identification of persons at risk, harm-reduction–informed patient education, and selected models for effective linkage to HCV treatment.

Debates & Discussions on the Evolving Role of JAK Inhibitors

Collaborative Care for Better Patient Outcomes

HIV as a Chronic Disease: A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities

Debates and Discussions Around Cardiovascular and Renal Outcomes

Why It Matters in OB/GYN Practice Today

Two-part CME/CE Series - Earn 1.0 Total Credit

Part 1: Video-Based Program - Best Practices in Communicating About Sexual Health: What's Your Style?

Compare and contrast patient-clinician interactions
What is your patient not telling you?
Tools, tips, and conversation-starters to avoid stigma and optimize engagement

Part 2: Case-Based Program - Manage This Patient: Preventing HIV Infection With PrEP

Assessing HIV risk and PrEP eligibility

Pre-PrEP testing and initiation of treatment

On-treatment monitoring and adherence/risk-reduction counseling

Improving Patient Outcomes Through Shared Clinical Decision Making

Debates and Discussions About Pustular Disease Subtypes

Let’s Talk Constipation

Realities, Challenges, and Opportunities to Improve Care

Chronic pain affects 100 million Americans. Certain patients with chronic pain are candidates for intrathecal (IT) therapy, which can mitigate some of the risks associated with systemic opioids. Following appropriate patient selection based on medical and psychiatric history and a physical exam, a patient can begin a trial with morphine or ziconotide, the 2 US Food and Drug Administration (FDA)–approved IT therapies. Monitoring for adverse events should continue after IT pump implantation, as should monitoring for catheter- or pump-related complications. This CME/CE-accredited Point of Care 201™ 2-part series discusses identification of candidates for IT therapy, available IT therapies, optimal treatment initiation and management, and both surgical implantation and pump refill techniques.

Realities, Challenges, and Opportunities to Improve Care

This activity is designed to update gastroenterologists, rheumatologists and other specialist clinicians on the latest evidence related to Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in disease pathophysiology and potential implications for future therapeutic strategies. The activity will provide foundational information, relevant across specialties.

Hot Topics in HBV, HCV, and NASH

HIV-Prevention Education for University Student Health Centers